PriceTargets.com logo

Aeglea BioTherapeutics - AGLE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.50
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 11/27/2023 05:00 PM ET
+0 (0.00%)
Get New Aeglea BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGLE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGLE

Analyst Price Target is $17.50
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aeglea BioTherapeutics in the last 3 months. The average price target is $17.50, with a high forecast of $22.50 and a low forecast of $12.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for AGLE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Aeglea BioTherapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$8.75 ➝ $12.50Low
7/25/2023Stifel NicolausInitiated CoverageBuy$22.50Low
4/12/2023JonestradingReiterated RatingBuy ➝ HoldLow
4/12/2023Lifesci CapitalDowngradeOutperform ➝ Market PerformLow
4/12/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightLow
3/3/2023HC WainwrightReiterated RatingNeutral$25.00Low
11/1/2022Piper SandlerBoost Target$37.50N/A
10/28/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$37.50 ➝ $50.00Low
10/27/2022Piper SandlerUpgradeNeutral ➝ OverweightLow
8/25/2022JonestradingReiterated RatingBuy$75.00Low
8/9/2022Wells Fargo & CompanyLower TargetEqual Weight$50.00 ➝ $37.50Low
6/2/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
6/2/2022HC WainwrightDowngradeBuy ➝ Neutral$425.00 ➝ $25.00High
6/2/2022Piper SandlerDowngradeOverweight ➝ Neutral$100.00 ➝ $25.00High
5/23/2022Piper SandlerLower TargetOverweight$175.00 ➝ $100.00Low
5/6/2022Piper SandlerLower Target$225.00 ➝ $175.00Low
5/5/2022HC WainwrightLower Target$500.00 ➝ $425.00Low
12/6/2021Piper SandlerLower TargetOverweight ➝ Overweight$300.00 ➝ $225.00High
11/5/2021Lifesci CapitalReiterated RatingOutperformLow
8/6/2021Evercore ISIInitiated CoverageBuy$500.00Medium
6/24/2021Needham & Company LLCReiterated RatingBuy$300.00High
11/9/2020HC WainwrightReiterated RatingBuy$425.00 ➝ $375.00High
10/23/2020Lifesci CapitalReiterated RatingOutperformMedium
9/16/2020HC WainwrightReiterated RatingBuy$425.00Medium
8/10/2020Needham & Company LLCReiterated RatingBuy$275.00High
5/26/2020Needham & Company LLCInitiated CoverageBuy$275.00Low
5/8/2020HC WainwrightLower TargetBuy$450.00 ➝ $425.00Low
5/7/2020Needham & Company LLCLower TargetBuy$350.00 ➝ $275.00High
5/4/2020Piper SandlerInitiated CoverageOverweight$300.00Medium
4/30/2020HC WainwrightLower TargetBuy$600.00 ➝ $450.00Low
4/8/2020Needham & Company LLCReiterated RatingBuy$350.00High
2/26/2020Needham & Company LLCReiterated RatingBuy ➝ Average$350.00High
2/25/2020HC WainwrightBoost TargetBuy$500.00 ➝ $600.00High
6/3/2019HC WainwrightReiterated RatingBuy$500.00Low
5/21/2019HC WainwrightInitiated CoverageBuy$500.00 ➝ $500.00High
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aeglea BioTherapeutics logo
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $11.47
Low: $9.47
High: $13.76

52 Week Range

Now: N/A

Volume

43,300 shs

Average Volume

95,409 shs

Market Capitalization

$48.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Aeglea BioTherapeutics?

The following sell-side analysts have issued reports on Aeglea BioTherapeutics in the last year: Stifel Nicolaus, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for AGLE.

What is the current price target for Aeglea BioTherapeutics?

2 Wall Street analysts have set twelve-month price targets for Aeglea BioTherapeutics in the last year. Their average twelve-month price target is $17.50. Stifel Nicolaus has the highest price target set, predicting AGLE will reach $22.50 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $12.50 for Aeglea BioTherapeutics in the next year.
View the latest price targets for AGLE.

What is the current consensus analyst rating for Aeglea BioTherapeutics?

Aeglea BioTherapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AGLE.

What other companies compete with Aeglea BioTherapeutics?

Other companies that are similar to Aeglea BioTherapeutics include Daré Bioscience, Apollomics, Jaguar Health, CalciMedica and Gain Therapeutics. Learn More about companies similar to Aeglea BioTherapeutics.

How do I contact Aeglea BioTherapeutics' investor relations team?

Aeglea BioTherapeutics' physical mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company's listed phone number is (512) 942-2935 and its investor relations email address is [email protected]. The official website for Aeglea BioTherapeutics is www.aegleabio.com. Learn More about contacing Aeglea BioTherapeutics investor relations.